Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STACT
- Development stage
- Unknown
- Lead developer
- Actym Therapeutics
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies
- Administration
- Intravenous
01
Overview
STACT (S. Typhimurium-Attenuated Cancer Therapy) is a patent-protected, microbial-based immunotherapeutic technology platform developed by Actym Therapeutics for treating solid tumors. [3-13, 3-14] The platform utilizes a genetically engineered, attenuated strain of *Salmonella Typhimurium* as a vehicle that can be administered systemically. [1, 2] In preclinical studies, STACT was shown to specifically enrich in solid tumors rather than healthy tissue. [3-15, 3-16] Once inside the tumor, the bacteria deliver multiple immuno-modulatory payloads directly to tumor-resident immune cells, particularly phagocytic antigen-presenting cells (APCs), activating both innate and adaptive immunity. [2, 3-15, 3-16, 6] This approach enables the local delivery of potent therapeutic combinations that would be too toxic for systemic administration via conventional methods. [1, 3-17] The lead clinical candidate from this platform is ACTM-838, which delivers an engineered IL-15plex and a STING agonist. [2, 3]
- Other names
- S. Typhimurium-Attenuated Cancer Therapy
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on STACT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STACT.